BioPorto A/S Stock

Equities

BIOPOR

DK0011048619

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Copenhagen 10:59:39 2024-04-24 am EDT 5-day change 1st Jan Change
1.228 DKK -0.16% Intraday chart for BioPorto A/S -3.61% -41.24%
Sales 2024 * 40M 5.73M Sales 2025 * - Capitalization 467M 66.92M
Net income 2024 * -38M -5.45M Net income 2025 * - EV / Sales 2024 * 11.7 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-12.3 x
P/E ratio 2025 *
-
Employees 29
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.17%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on BioPorto A/S

1 day-0.49%
1 week-3.45%
Current month-5.96%
1 month-6.82%
3 months-42.52%
6 months-18.22%
Current year-41.15%
More quotes
1 week
1.21
Extreme 1.212
1.28
1 month
1.21
Extreme 1.212
1.45
Current year
1.21
Extreme 1.212
2.35
1 year
1.07
Extreme 1.07
3.85
3 years
1.00
Extreme 1.002
5.00
5 years
1.00
Extreme 1.002
8.24
10 years
1.00
Extreme 1.002
8.24
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 13-07-17
Chief Tech/Sci/R&D Officer - 20-11-30
Chief Tech/Sci/R&D Officer - 22-06-30
Members of the board TitleAgeSince
Chairman 65 21-04-28
Director/Board Member 74 21-04-28
Chief Executive Officer 64 13-07-17
More insiders
Date Price Change Volume
24-04-24 1.228 -0.16% 132 753
24-04-23 1.23 +0.65% 226,003
24-04-22 1.222 -2.86% 386,107
24-04-19 1.258 +0.32% 274,377
24-04-18 1.254 -1.57% 127,316

Delayed Quote Nasdaq Copenhagen, April 24, 2024 at 07:34 am EDT

More quotes
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.23 DKK
Average target price
5 DKK
Spread / Average Target
+306.50%
Consensus
  1. Stock Market
  2. Equities
  3. BIOPOR Stock